Cardiotoxicity of Immune Checkpoint Inhibitors

PURPOSE OF REVIEW: Immune checkpoint inhibitors (ICIs) have improved the survival of several cancers. However, they may cause a wide range of immune-related adverse events (irAEs). While most irAEs are manageable with temporary cessation of ICI and immunosuppression, cardiovascular toxicity can be a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Curr Oncol Rep
Autors principals: Patel, Rushin P., Parikh, Rohan, Gunturu, Krishna S., Tariq, Rana Zouveenoor, Dani, Sourbha S., Ganatra, Sarju, Nohria, Anju
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2021
Matèries:
Cardio-oncology (EH Yang, Section Editor)
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8088903/
https://ncbi.nlm.nih.gov/pubmed/33937956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11912-021-01070-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars